Methotrexate-d3 (diammonium)

Methotrexate-d3 (diammonium)

• UNSPSC Description: Methotrexate-d3 diammonium is the deuterium labeled Methotrexate diammonium. Methotrexate (Amethopterin), an antimetabolite and antifolate agent, inhibits the enzyme dihydrofolate reductase, thereby preventing the conversion of folic acid into tetrahydrofolate, and inhibiting DNA synthesis. Methotrexate, also an immunosuppressant and antineoplastic agent, is used for the research of rheumatoid arthritis and a number of different cancers (such as acute lymphoblastic leukemia)[1][2][3].
• Target Antigen: Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: Others
• Applications: Metabolism-protein/nucleotide metabolism
• Field of Research: Cancer; Metabolic Disease; Inflammation/Immunology
• Solubility: DMSO : 50 mg/mL (ultrasonic)
• Smiles: NC1=NC(N)=NC2=C1N=C(CN(C3=CC=C(C(N[C@H](C(O)=O)CCC(O)=O)=O)C=C3)C([2H])([2H])[2H])C=N2.N.N
• Molecular Weight: 491.52
• References & Citations: [1]Tian H, et al. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65(3):168-73.|[2]Swierkot J, et al. Methotrexate in rheumatoid arthritis. Pharmacol Rep. 2006 Jul-Aug;58(4):473-92.|[3]Ehab Tousson, et al. The Effect of L-carnitine on Amethopterin-induced Toxicity in Rat Large Intestine. Journal of Cancer Research and Treatment, 2014 2 (3), pp 55-63.
• Shipping Conditions: Blue Ice
• Clinical Information: No Development Reported